Critical reviews in oncology/hematology最新文献_第5页

Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies 以伊立替康为基础的胶质母细胞瘤治疗的创新方法：药物传递和联合策略的进展。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-22 DOI: 10.1016/j.critrevonc.2026.105144

Chou-Yi Hsu , Mirza R. Baig , Pareshkumar N. Patel , Gunjan Singh , Ihab M. Abdelrahim , Monthar Kadhem , Vimal Arora , Venkata Ramana Maddula , Priya Priyadarshini Nayak , Muhammad Shahid Iqbal

Glioblastoma (GBM) remains one of the most lethal human malignancies, characterized by profound heterogeneity, therapeutic resistance, and limited drug penetration across the blood–brain barrier (BBB). Irinotecan (CPT-11), a topoisomerase I inhibitor converted to its active metabolite SN-38, has emerged as a potential chemotherapeutic alternative for GBM due to its distinct mechanism of action and non–cross-resistance with temozolomide (TMZ). However, early clinical trials revealed limited efficacy, largely constrained by subtherapeutic intratumoral exposure, pharmacogenetic variability, and systemic toxicity. Recent advances have redefined the therapeutic landscape of irinotecan through three convergent strategies: biomarker-guided precision, rational combination design, and innovative drug-delivery systems.

Biomarker studies have identified predictive indicators such as TIMP-1 expression, TDP1/TOP1 activity ratio, and EGFRvIII-associated replication stress, providing a framework for patient stratification and response prediction. Mechanistic research has expanded irinotecan’s therapeutic logic beyond DNA damage, uncovering roles in p21-mediated senescence and metabolic-epigenetic modulation when combined with checkpoint inhibitors or senolytic agents. Parallel innovations in delivery ranging from liposomal and nanoparticle formulations to implantable PLGA devices, peptide–drug conjugates, and MRI-guided convection-enhanced delivery have achieved sustained intraparenchymal SN-38 exposure while minimizing systemic burden.

Collectively, these developments mark a translational shift from empirical cytotoxic therapy toward a modular, precision-engineered platform. The integration of biomarker discovery, molecularly rational combinations, and locoregional delivery systems positions irinotecan as a key component of next-generation GBM treatment paradigms, with the potential to overcome historical barriers such as BBB impermeability and therapeutic resistance.

胶质母细胞瘤（GBM）仍然是最致命的人类恶性肿瘤之一，其特点是严重的异质性、治疗耐药性和有限的药物穿透血脑屏障（BBB）。伊立替康（CPT-11）是一种拓扑异构酶I抑制剂，可转化为其活性代谢物SN-38，由于其独特的作用机制和与替莫唑胺（TMZ）的无交叉耐药，已成为GBM的潜在化疗替代品。然而，早期临床试验显示疗效有限，主要受亚治疗性肿瘤内暴露、药物遗传变异和全身毒性的限制。最近的进展通过三种策略重新定义了伊立替康的治疗前景：生物标志物引导的精度、合理的组合设计和创新的给药系统。生物标志物研究已经确定了TIMP-1表达、TDP1/TOP1活性比和egfrviii相关复制应激等预测指标，为患者分层和反应预测提供了框架。机制研究已经将伊立替康的治疗逻辑扩展到DNA损伤之外，揭示了当与检查点抑制剂或抗衰老药物联合使用时，伊立替康在p21介导的衰老和代谢-表观遗传调节中的作用。从脂质体和纳米颗粒制剂到植入式PLGA装置、肽-药物偶联物和mri引导对流增强给药的平行创新已经实现了持续的肺实质内SN-38暴露，同时最大限度地减少了全身负担。总的来说，这些发展标志着从经验性细胞毒性治疗向模块化、精密工程平台的转化转变。生物标志物发现、分子合理组合和局部区域给药系统的整合，使伊立替康成为下一代GBM治疗范例的关键组成部分，具有克服血脑屏障不渗透性和治疗耐药性等历史障碍的潜力。

{"title":"Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies","authors":"Chou-Yi Hsu , Mirza R. Baig , Pareshkumar N. Patel , Gunjan Singh , Ihab M. Abdelrahim , Monthar Kadhem , Vimal Arora , Venkata Ramana Maddula , Priya Priyadarshini Nayak , Muhammad Shahid Iqbal","doi":"10.1016/j.critrevonc.2026.105144","DOIUrl":"10.1016/j.critrevonc.2026.105144","url":null,"abstract":"<div><div>Glioblastoma (GBM) remains one of the most lethal human malignancies, characterized by profound heterogeneity, therapeutic resistance, and limited drug penetration across the blood–brain barrier (BBB). Irinotecan (CPT-11), a topoisomerase I inhibitor converted to its active metabolite SN-38, has emerged as a potential chemotherapeutic alternative for GBM due to its distinct mechanism of action and non–cross-resistance with temozolomide (TMZ). However, early clinical trials revealed limited efficacy, largely constrained by subtherapeutic intratumoral exposure, pharmacogenetic variability, and systemic toxicity. Recent advances have redefined the therapeutic landscape of irinotecan through three convergent strategies: biomarker-guided precision, rational combination design, and innovative drug-delivery systems.</div><div>Biomarker studies have identified predictive indicators such as TIMP-1 expression, TDP1/TOP1 activity ratio, and EGFRvIII-associated replication stress, providing a framework for patient stratification and response prediction. Mechanistic research has expanded irinotecan’s therapeutic logic beyond DNA damage, uncovering roles in p21-mediated senescence and metabolic-epigenetic modulation when combined with checkpoint inhibitors or senolytic agents. Parallel innovations in delivery ranging from liposomal and nanoparticle formulations to implantable PLGA devices, peptide–drug conjugates, and MRI-guided convection-enhanced delivery have achieved sustained intraparenchymal SN-38 exposure while minimizing systemic burden.</div><div>Collectively, these developments mark a translational shift from empirical cytotoxic therapy toward a modular, precision-engineered platform. The integration of biomarker discovery, molecularly rational combinations, and locoregional delivery systems positions irinotecan as a key component of next-generation GBM treatment paradigms, with the potential to overcome historical barriers such as BBB impermeability and therapeutic resistance.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105144"},"PeriodicalIF":5.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy TGF-β介导的NK细胞功能抑制及其在肿瘤免疫治疗中的靶向策略

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-22 DOI: 10.1016/j.critrevonc.2026.105141

Bo Wang , Jiacheng Bi

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that can directly kill tumor cells or coordinate other immune cells to exert antitumor effects. Transforming growth factor-β (TGF-β) is a potent inhibitory cytokine in the tumor microenvironment (TME), and its suppression of NK-cell function is an important contributor to tumor immune evasion. TGF-β can inhibit NK-cell activation and effector functions, impair NK-cell proliferation and migration, and induce the conversion of NK cells into type 1 innate lymphoid cells (ILC1s). Therefore, blocking or “hijacking” TGF-β signalling is a promising strategy to enhance the therapeutic efficacy of NK-cell-based immunotherapy. In preclinical models and, to a lesser extent, in early-phase clinical trials of TGF-β pathway inhibitors, strategies to reverse TGF-β-mediated suppression mainly include delivery of small-molecule inhibitors and recombinant protein drugs targeting TGF-β and its signalling pathways, as well as genetic engineering of NK cells. This review summarizes TGF-β signal transduction, the antitumor biological functions of NK cells, the multifaceted inhibitory effects of TGF-β on NK cells within the TME, and NK-cell-based tumor immunotherapy approaches that target TGF-β. We further highlight the limitations of current strategies and point to future directions for more precise and controllable interventions.

自然杀伤细胞（Natural killer， NK）是先天免疫系统的细胞毒性淋巴细胞，可直接杀伤肿瘤细胞或协同其他免疫细胞发挥抗肿瘤作用。转化生长因子-β (TGF-β)是肿瘤微环境（tumor microenvironment， TME）中一种有效的抑制细胞因子，其对nk细胞功能的抑制是肿瘤免疫逃避的重要因素。TGF-β可以抑制NK细胞的活化和效应功能，损害NK细胞的增殖和迁移，诱导NK细胞向1型先天淋巴样细胞（ILC1s）转化。因此，阻断或“劫持”TGF-β信号是提高nk细胞免疫治疗疗效的一种有前景的策略。在TGF-β途径抑制剂的临床前模型和较小程度的早期临床试验中，逆转TGF-β介导抑制的策略主要包括靶向TGF-β及其信号通路的小分子抑制剂和重组蛋白药物的递送，以及NK细胞的基因工程。本文综述了TGF-β信号转导、NK细胞的抗肿瘤生物学功能、TGF-β对TME内NK细胞的多方面抑制作用以及以TGF-β为靶点的NK细胞肿瘤免疫治疗方法。我们进一步强调了当前策略的局限性，并指出了未来更精确和可控干预的方向。

{"title":"TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy","authors":"Bo Wang , Jiacheng Bi","doi":"10.1016/j.critrevonc.2026.105141","DOIUrl":"10.1016/j.critrevonc.2026.105141","url":null,"abstract":"<div><div>Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that can directly kill tumor cells or coordinate other immune cells to exert antitumor effects. Transforming growth factor-β (TGF-β) is a potent inhibitory cytokine in the tumor microenvironment (TME), and its suppression of NK-cell function is an important contributor to tumor immune evasion. TGF-β can inhibit NK-cell activation and effector functions, impair NK-cell proliferation and migration, and induce the conversion of NK cells into type 1 innate lymphoid cells (ILC1s). Therefore, blocking or “hijacking” TGF-β signalling is a promising strategy to enhance the therapeutic efficacy of NK-cell-based immunotherapy. In preclinical models and, to a lesser extent, in early-phase clinical trials of TGF-β pathway inhibitors, strategies to reverse TGF-β-mediated suppression mainly include delivery of small-molecule inhibitors and recombinant protein drugs targeting TGF-β and its signalling pathways, as well as genetic engineering of NK cells. This review summarizes TGF-β signal transduction, the antitumor biological functions of NK cells, the multifaceted inhibitory effects of TGF-β on NK cells within the TME, and NK-cell-based tumor immunotherapy approaches that target TGF-β. We further highlight the limitations of current strategies and point to future directions for more precise and controllable interventions.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105141"},"PeriodicalIF":5.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in locally advanced head and neck squamous cell carcinoma: The current status and future outlook 局部晚期头颈部鳞状细胞癌的免疫治疗现状及展望。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-22 DOI: 10.1016/j.critrevonc.2026.105145

Bahadır Köylü , Fatih Selçukbiricik , Sercan Aksoy , Deniz Can Güven

Head and neck squamous cell carcinoma presents a significant global health burden, with the majority of cases diagnosed at a locally advanced stage requiring multimodal therapy. While the immune checkpoint inhibitors have transformed outcomes in the recurrent/metastatic setting, their role in locally advanced head and neck squamous cell carcinoma is still evolving. In resectable disease, two recent phase III trials (KEYNOTE-689 and NIVOPOSTOP) have demonstrated meaningful improvements in event-free and disease-free survival, supporting the integration of perioperative and adjuvant immunotherapy into curative strategies. However, the data on the efficacy of immune checkpoint inhibitors in unresectable locally advanced head and neck squamous cell carcinoma remains inconsistent, underscoring the need for more precise patient selection and biomarker-driven approaches. Therapeutic strategies optimized for the timing and sequencing of immune checkpoint inhibitors in accordance with tumor microenvironment dynamics may improve clinical outcomes. Additionally, emerging immunotherapeutics, such as bispecific antibodies, oncolytic viruses, and chimeric antigen receptor T cell therapies, represents a promising frontier in the management of locally advanced head and neck squamous cell carcinoma. Considering the recent advances of the field, we aimed to synthesize current evidence and explore future directions for immunotherapy in locally advanced head and neck squamous cell carcinoma.

头颈部鳞状细胞癌是一个重大的全球健康负担，大多数病例被诊断为局部晚期，需要多模式治疗。虽然免疫检查点抑制剂已经改变了复发/转移的预后，但它们在局部晚期头颈部鳞状细胞癌中的作用仍在发展。在可切除的疾病中，最近的两项III期试验（KEYNOTE-689和nivoopstop）显示无事件和无病生存期有意义的改善，支持将围手术期和辅助免疫治疗纳入治疗策略。然而，免疫检查点抑制剂在不可切除的局部晚期头颈部鳞状细胞癌中的疗效数据仍然不一致，强调需要更精确的患者选择和生物标志物驱动的方法。根据肿瘤微环境动力学优化免疫检查点抑制剂的时间和序列的治疗策略可能会改善临床结果。此外，新兴的免疫疗法，如双特异性抗体、溶瘤病毒和嵌合抗原受体T细胞疗法，在局部晚期头颈部鳞状细胞癌的治疗中代表了一个有前景的前沿。考虑到该领域的最新进展，我们旨在综合现有证据并探讨局部晚期头颈部鳞状细胞癌免疫治疗的未来方向。

{"title":"Immunotherapy in locally advanced head and neck squamous cell carcinoma: The current status and future outlook","authors":"Bahadır Köylü , Fatih Selçukbiricik , Sercan Aksoy , Deniz Can Güven","doi":"10.1016/j.critrevonc.2026.105145","DOIUrl":"10.1016/j.critrevonc.2026.105145","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma presents a significant global health burden, with the majority of cases diagnosed at a locally advanced stage requiring multimodal therapy. While the immune checkpoint inhibitors have transformed outcomes in the recurrent/metastatic setting, their role in locally advanced head and neck squamous cell carcinoma is still evolving. In resectable disease, two recent phase III trials (KEYNOTE-689 and NIVOPOSTOP) have demonstrated meaningful improvements in event-free and disease-free survival, supporting the integration of perioperative and adjuvant immunotherapy into curative strategies. However, the data on the efficacy of immune checkpoint inhibitors in unresectable locally advanced head and neck squamous cell carcinoma remains inconsistent, underscoring the need for more precise patient selection and biomarker-driven approaches. Therapeutic strategies optimized for the timing and sequencing of immune checkpoint inhibitors in accordance with tumor microenvironment dynamics may improve clinical outcomes. Additionally, emerging immunotherapeutics, such as bispecific antibodies, oncolytic viruses, and chimeric antigen receptor T cell therapies, represents a promising frontier in the management of locally advanced head and neck squamous cell carcinoma. Considering the recent advances of the field, we aimed to synthesize current evidence and explore future directions for immunotherapy in locally advanced head and neck squamous cell carcinoma.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105145"},"PeriodicalIF":5.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transforming role of cancer associated fibroblasts: From therapeutic barriers to promising targets 癌症相关成纤维细胞的转化作用：从治疗障碍到有希望的靶点。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-22 DOI: 10.1016/j.critrevonc.2026.105143

Jing Chang , Xiang Yu , Nan Xiong , Mingxuan Zhu , Changjiang Yang , Shidong Zhao , Caihong Wang , Shan Wang , Yingjiang Ye , Zhanlong Shen

Tumor microenvironment (TME) serves as a critical mediator in cancer progression and treatment response, with cancer-associated fibroblasts (CAFs) recognized as core regulators of stromal-tumor interactions. As essential components of the TME, CAFs orchestrate tumor progression and therapy resistance through multifaceted mechanisms, including extracellular matrix (ECM) remodeling, angiogenesis modulation, and immune regulation, which collectively establish a complex regulatory network. Owing to their functional heterogeneity and potent tumor-promoting properties, CAFs have emerged as promising targets for novel anti-tumor therapies. This review highlights recent advances in the understanding of CAFs, focusing on their intricate interactions within the TME and their synergistic roles in promoting therapy resistance in cancer. Furthermore, we also discuss current CAF-targeted therapeutic strategies and ongoing clinical trials, and propose future research directions to further advance this field.

肿瘤微环境（Tumor microenvironment， TME）在癌症进展和治疗反应中起着重要的调节作用，而癌症相关成纤维细胞（cancer-associated fibroblasts, CAFs）被认为是基质-肿瘤相互作用的核心调节因子。作为TME的重要组成部分，CAFs通过多方面的机制协调肿瘤的进展和治疗耐药性，包括细胞外基质（ECM）重塑、血管生成调节和免疫调节，这些机制共同建立了一个复杂的调节网络。由于其功能异质性和有效的肿瘤促进特性，CAFs已成为新型抗肿瘤治疗的有希望的靶点。本文综述了对CAFs的最新研究进展，重点关注它们在TME内的复杂相互作用以及它们在促进癌症治疗耐药中的协同作用。此外，我们还讨论了目前的针对caf的治疗策略和正在进行的临床试验，并提出了未来的研究方向，以进一步推进这一领域。

{"title":"Transforming role of cancer associated fibroblasts: From therapeutic barriers to promising targets","authors":"Jing Chang , Xiang Yu , Nan Xiong , Mingxuan Zhu , Changjiang Yang , Shidong Zhao , Caihong Wang , Shan Wang , Yingjiang Ye , Zhanlong Shen","doi":"10.1016/j.critrevonc.2026.105143","DOIUrl":"10.1016/j.critrevonc.2026.105143","url":null,"abstract":"<div><div>Tumor microenvironment (TME) serves as a critical mediator in cancer progression and treatment response, with cancer-associated fibroblasts (CAFs) recognized as core regulators of stromal-tumor interactions. As essential components of the TME, CAFs orchestrate tumor progression and therapy resistance through multifaceted mechanisms, including extracellular matrix (ECM) remodeling, angiogenesis modulation, and immune regulation, which collectively establish a complex regulatory network. Owing to their functional heterogeneity and potent tumor-promoting properties, CAFs have emerged as promising targets for novel anti-tumor therapies. This review highlights recent advances in the understanding of CAFs, focusing on their intricate interactions within the TME and their synergistic roles in promoting therapy resistance in cancer. Furthermore, we also discuss current CAF-targeted therapeutic strategies and ongoing clinical trials, and propose future research directions to further advance this field.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105143"},"PeriodicalIF":5.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circular RNAs: A key modulator of established cancer hallmarks 环状rna：已建立的癌症特征的关键调节剂。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-22 DOI: 10.1016/j.critrevonc.2026.105146

Md Abdus Samad , Iftikhar Ahmad , Shazi Shakil , Syed Kashif Zaidi , Samina Wasi , Fahad A. Al-Abbasi , Mohammad Hassan Alhashmi , Shams Tabrez

Cancer encompasses a diverse range of disease conditions marked by the uncontrolled growth of abnormal cells and is often associated with high recurrence rates. The development and progression of cancer are closely linked to the disruption of key molecular pathways that regulate cellular and tissue homeostasis. Among the various molecular players involved, circular RNAs (circRNAs) have gained increasing attention from the scientific community because of their aberrant expression in various cancer types, leading to its progression and development. CircRNAs represent a distinct class of covalently closed RNA with distinct tissue- and cell-specific expression profiles and are essential for controlling key cellular processes. It has emerged as a crucial regulatory molecule that contributes to numerous hallmarks of cancer, such as enhanced cell proliferation, growth suppression evasion, resistance to cell death, induction of angiogenesis, invasion and metastasis, maintenance of cancer stem cells, immune evasion, metabolic reprogramming, promotion of inflammation, impairment of DNA damage, genomic instability, non-mutational epigenetic reprogramming, and therapeutic resistance. This review aims to enhance our understanding on the role of circRNAs on several cancer hallmarks and promote further research into their underlying mechanism of action, to identify and utilize them as potential therapeutic strategies.

癌症包括各种各样的疾病状况，其特征是异常细胞不受控制的生长，通常与高复发率有关。癌症的发生和发展与调节细胞和组织稳态的关键分子通路的破坏密切相关。在涉及的各种分子参与者中，环状rna （circRNAs）因其在各种癌症类型中的异常表达，导致其进展和发展而越来越受到科学界的关注。CircRNAs代表了一类独特的共价封闭RNA，具有独特的组织和细胞特异性表达谱，对于控制关键的细胞过程至关重要。它已成为一个重要的调控分子，有助于许多癌症的特征，如增强细胞增殖，逃避生长抑制，抵抗细胞死亡，诱导血管生成，侵袭和转移，维持癌症干细胞，免疫逃避，代谢重编程，促进炎症，DNA损伤损伤，基因组不稳定，非突变表观遗传重编程和治疗抗性。本综述旨在增强我们对环状rna在几种癌症类型中的作用的理解，并促进对其潜在机制的进一步研究，以识别和利用它们作为潜在的治疗策略。

{"title":"Circular RNAs: A key modulator of established cancer hallmarks","authors":"Md Abdus Samad , Iftikhar Ahmad , Shazi Shakil , Syed Kashif Zaidi , Samina Wasi , Fahad A. Al-Abbasi , Mohammad Hassan Alhashmi , Shams Tabrez","doi":"10.1016/j.critrevonc.2026.105146","DOIUrl":"10.1016/j.critrevonc.2026.105146","url":null,"abstract":"<div><div>Cancer encompasses a diverse range of disease conditions marked by the uncontrolled growth of abnormal cells and is often associated with high recurrence rates. The development and progression of cancer are closely linked to the disruption of key molecular pathways that regulate cellular and tissue homeostasis. Among the various molecular players involved, circular RNAs (circRNAs) have gained increasing attention from the scientific community because of their aberrant expression in various cancer types, leading to its progression and development. CircRNAs represent a distinct class of covalently closed RNA with distinct tissue- and cell-specific expression profiles and are essential for controlling key cellular processes. It has emerged as a crucial regulatory molecule that contributes to numerous hallmarks of cancer, such as enhanced cell proliferation, growth suppression evasion, resistance to cell death, induction of angiogenesis, invasion and metastasis, maintenance of cancer stem cells, immune evasion, metabolic reprogramming, promotion of inflammation, impairment of DNA damage, genomic instability, non-mutational epigenetic reprogramming, and therapeutic resistance. This review aims to enhance our understanding on the role of circRNAs on several cancer hallmarks and promote further research into their underlying mechanism of action, to identify and utilize them as potential therapeutic strategies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105146"},"PeriodicalIF":5.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The novel roles of RNA 5-methylcytosine modification in gastrointestinal tract cancers RNA 5-甲基胞嘧啶修饰在胃肠道癌症中的新作用。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-20 DOI: 10.1016/j.critrevonc.2026.105140

Chenye Xi , Ye Gao , Huishan Jiang , Yan Bian , Chuting Yu , Zheran Chen , Wei Wang , Lei Xin , Han Lin , Luowei Wang

Gastrointestinal tract cancers, including esophageal carcinoma (ESCA), gastric cancer (GC), and colorectal carcinoma (CRC), are among the most common malignant tumors with high morbidity and mortality rates, posing an increasingly significant burden on social healthcare systems. Recent evidence revealing the association between RNA modifications (collectively termed epitranscriptomics) and the tumorigenesis of gastrointestinal tract cancers has provided new insights into their pathogenesis. Among these modifications, 5-methylcytosine (m5C) is one of the most prevalent. In this narrative review, we discuss the regulators and functions of RNA m5C modification, summarize the recent studies on the roles of m5C modification in gastrointestinal tract cancer cells, briefly explore the association between RNA m5C modification and the tumor microenvironment (TME), and provide insights into its potential clinical applications as well as the remaining challenges in utilizing m5C modification for the management of gastrointestinal tract cancers. This review is based on comprehensive literature searches conducted primarily in PubMed, with no restrictions on publication date. Relevant articles were selected according to their relevance to the scope and objectives of this review. Although increasing evidence has elucidated the molecular mechanisms by which m5C RNA modification regulates the development and progression of gastrointestinal tract cancers, clinical evidence supporting its application in early screening or as a therapeutic target remains limited. Current findings are mainly derived from experimental studies and exploratory clinical studies, suggesting the gap between mechanistic insights and clinical translation.

包括食管癌（ESCA）、胃癌（GC）和结直肠癌（CRC）在内的胃肠道癌症是最常见的恶性肿瘤，发病率和死亡率都很高，对社会卫生保健系统造成了越来越大的负担。最近的证据揭示了RNA修饰（统称为表观转录组学）与胃肠道癌症的肿瘤发生之间的关联，为其发病机制提供了新的见解。在这些修饰中，5-甲基胞嘧啶（m5C）是最普遍的修饰之一。在这篇综述中，我们讨论了RNA m5C修饰的调控因子和功能，总结了最近关于m5C修饰在胃肠道癌细胞中的作用的研究，简要探讨了RNA m5C修饰与肿瘤微环境（TME）的关系，并对其潜在的临床应用以及利用m5C修饰治疗胃肠道癌症的挑战提出了见解。本综述基于主要在PubMed上进行的综合文献检索，对出版日期没有限制。根据其与本综述的范围和目标的相关性选择相关文章。尽管越来越多的证据阐明了m5C RNA修饰调节胃肠道癌症发生和进展的分子机制，但支持其早期筛查或作为治疗靶点的临床证据仍然有限。目前的研究结果主要来自实验研究和探索性临床研究，表明机理认识与临床转化之间存在差距。

{"title":"The novel roles of RNA 5-methylcytosine modification in gastrointestinal tract cancers","authors":"Chenye Xi , Ye Gao , Huishan Jiang , Yan Bian , Chuting Yu , Zheran Chen , Wei Wang , Lei Xin , Han Lin , Luowei Wang","doi":"10.1016/j.critrevonc.2026.105140","DOIUrl":"10.1016/j.critrevonc.2026.105140","url":null,"abstract":"<div><div>Gastrointestinal tract cancers, including esophageal carcinoma (ESCA), gastric cancer (GC), and colorectal carcinoma (CRC), are among the most common malignant tumors with high morbidity and mortality rates, posing an increasingly significant burden on social healthcare systems. Recent evidence revealing the association between RNA modifications (collectively termed epitranscriptomics) and the tumorigenesis of gastrointestinal tract cancers has provided new insights into their pathogenesis. Among these modifications, 5-methylcytosine (m5C) is one of the most prevalent. In this narrative review, we discuss the regulators and functions of RNA m5C modification, summarize the recent studies on the roles of m5C modification in gastrointestinal tract cancer cells, briefly explore the association between RNA m5C modification and the tumor microenvironment (TME), and provide insights into its potential clinical applications as well as the remaining challenges in utilizing m5C modification for the management of gastrointestinal tract cancers. This review is based on comprehensive literature searches conducted primarily in PubMed, with no restrictions on publication date. Relevant articles were selected according to their relevance to the scope and objectives of this review. Although increasing evidence has elucidated the molecular mechanisms by which m5C RNA modification regulates the development and progression of gastrointestinal tract cancers, clinical evidence supporting its application in early screening or as a therapeutic target remains limited. Current findings are mainly derived from experimental studies and exploratory clinical studies, suggesting the gap between mechanistic insights and clinical translation.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105140"},"PeriodicalIF":5.6,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Efficacy and safety of boron neutron capture therapy for locally recurrent head and neck cancer” [Crit. Rev. Oncol./Hematol. 218 (2026) 105101] “硼中子俘获治疗局部复发性头颈癌的疗效和安全性”的勘误表[Crit]。启Oncol. /内科杂志。[218(2026) 105101]。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-19 DOI: 10.1016/j.critrevonc.2026.105125

Xing Sun , Yuchen Liu , Zhiyi Xue , Bo Cheng , Ruiping Zhang , Liping Li , Weicheng Huang , Qingxu Song , Yufeng Cheng

引用次数: 0

Harnessing the connection of the Wnt/beta-catenin pathway and other signaling pathways in glioblastoma multiforme 利用多形性胶质母细胞瘤中Wnt/ β -连环蛋白通路和其他信号通路的连接。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-15 DOI: 10.1016/j.critrevonc.2026.105127

Ali Nakhaei , Sadaf Afshari , Elmira Mohatshami , Mohammad Jalili-Nik , Mahsa Jalali , Kasim Sakran Abass , Amir R. Afshari , Prashant Kesharwani , Amirhossein Sahebkar

Finding the proper and most effective treatment is significant because glioblastoma (GB), the most common and aggressive type of brain tumor, has been very hard for the healthcare system to deal with. Usually, standard treatments for this type of tumor take a long time to work. Even when they do, they can cause a lot of harmful side effects. One possible way to do this is to look at essential signaling pathways, especially the Wnt/beta-catenin pathway. This pathway controls some cellular connections in both healthy and unhealthy states of development. Recent findings have clarified the unique anticancer characteristics of the Wnt/beta-catenin pathway and its interrelations with other cellular pathways. These advantages have increased hopes for finding the right treatments for all types of cancer, even GB. A suggested answer focuses on critical signaling pathways, especially the Wnt/beta-catenin pathway. This pathway regulates various cellular interactions in both normal development and disease states. Recent discoveries have elucidated the distinctive anticancer properties of the Wnt/beta-catenin pathway and its interactions with other cellular pathways. These benefits have made people hopeful that they will be able to find the best treatment for all types of cancer, including GB. ‎

胶质母细胞瘤（GB）是脑肿瘤中最常见、最具侵袭性的一种，对于医疗系统来说很难治疗，因此找到合适和最有效的治疗方法非常重要。通常，这种肿瘤的标准治疗需要很长时间才能奏效。即使他们这样做了，他们也会造成很多有害的副作用。一种可能的方法是观察基本的信号通路，特别是Wnt/ β -连环蛋白通路。这条通路控制着健康和不健康发育状态下的一些细胞连接。最近的研究结果阐明了Wnt/ β -catenin通路的独特抗癌特性及其与其他细胞通路的相互关系。这些优势增加了找到所有类型癌症的正确治疗方法的希望，甚至包括GB。一个建议的答案集中在关键的信号通路上，特别是Wnt/ β -连环蛋白通路。该通路调节正常发育和疾病状态下的各种细胞相互作用。最近的发现已经阐明了Wnt/ β -连环蛋白途径的独特抗癌特性及其与其他细胞途径的相互作用。这些益处使人们充满希望，他们将能够找到治疗所有类型癌症的最佳方法，包括GB。‎。

{"title":"Harnessing the connection of the Wnt/beta-catenin pathway and other signaling pathways in glioblastoma multiforme","authors":"Ali Nakhaei , Sadaf Afshari , Elmira Mohatshami , Mohammad Jalili-Nik , Mahsa Jalali , Kasim Sakran Abass , Amir R. Afshari , Prashant Kesharwani , Amirhossein Sahebkar","doi":"10.1016/j.critrevonc.2026.105127","DOIUrl":"10.1016/j.critrevonc.2026.105127","url":null,"abstract":"<div><div>Finding the proper and most effective treatment is significant because glioblastoma (GB), the most common and aggressive type of brain tumor, has been very hard for the healthcare system to deal with. Usually, standard treatments for this type of tumor take a long time to work. Even when they do, they can cause a lot of harmful side effects. One possible way to do this is to look at essential signaling pathways, especially the Wnt/beta-catenin pathway. This pathway controls some cellular connections in both healthy and unhealthy states of development. Recent findings have clarified the unique anticancer characteristics of the Wnt/beta-catenin pathway and its interrelations with other cellular pathways. These advantages have increased hopes for finding the right treatments for all types of cancer, even GB. A suggested answer focuses on critical signaling pathways, especially the Wnt/beta-catenin pathway. This pathway regulates various cellular interactions in both normal development and disease states. Recent discoveries have elucidated the distinctive anticancer properties of the Wnt/beta-catenin pathway and its interactions with other cellular pathways. These benefits have made people hopeful that they will be able to find the best treatment for all types of cancer, including GB. ‎</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105127"},"PeriodicalIF":5.6,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intratumoral microbiota: Distribution, mechanisms, and therapeutic implications 肿瘤内微生物群：分布、机制和治疗意义。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-14 DOI: 10.1016/j.critrevonc.2026.105128

Jiafei Ge , Lulu Gao , Lin Yu

Recent studies have increasingly highlighted the presence of microbiota within tumors and their substantial impact on tumor initiation, progression, and treatment efficacy. Intratumoral microbiota modulate tumor progression via multiple mechanisms, such as regulation of cancer cell proliferation, manipulation of immune microenvironment, and induction of the DNA damage. Notably, the distinct bacterial profiles associated with each tumor type can, in turn, promote or suppress tumor growth. Given the various mechanisms through which intratumoral microbiota influence tumor progression, a deeper understanding of their composition and functional roles in tumor dynamics is critical for the development of targeted therapies. In this review, we summarize current understanding and future perspectives of the bacterial lineages associated with different tumor types, discuss the mechanisms through which the intratumoral microbiome modulates tumor progression, and highlight emerging therapeutic strategies targeting intratumoral bacteria, including sonodynamic therapy (SDT), chemotherapy, immunotherapy, and oncolytic bacterial approaches.

最近的研究越来越强调肿瘤内微生物群的存在及其对肿瘤发生、进展和治疗效果的重大影响。肿瘤内微生物群通过多种机制调节肿瘤进展，如调节癌细胞增殖、操纵免疫微环境和诱导DNA损伤。值得注意的是，与每种肿瘤类型相关的不同细菌谱可以反过来促进或抑制肿瘤生长。鉴于肿瘤内微生物群影响肿瘤进展的各种机制，更深入地了解它们在肿瘤动力学中的组成和功能作用对于开发靶向治疗至关重要。在这篇综述中，我们总结了与不同肿瘤类型相关的细菌谱系的当前认识和未来观点，讨论了肿瘤内微生物组调节肿瘤进展的机制，并重点介绍了针对肿瘤内细菌的新兴治疗策略，包括声动力治疗（SDT）、化疗、免疫治疗和溶瘤细菌方法。

{"title":"Intratumoral microbiota: Distribution, mechanisms, and therapeutic implications","authors":"Jiafei Ge , Lulu Gao , Lin Yu","doi":"10.1016/j.critrevonc.2026.105128","DOIUrl":"10.1016/j.critrevonc.2026.105128","url":null,"abstract":"<div><div>Recent studies have increasingly highlighted the presence of microbiota within tumors and their substantial impact on tumor initiation, progression, and treatment efficacy. Intratumoral microbiota modulate tumor progression via multiple mechanisms, such as regulation of cancer cell proliferation, manipulation of immune microenvironment, and induction of the DNA damage. Notably, the distinct bacterial profiles associated with each tumor type can, in turn, promote or suppress tumor growth. Given the various mechanisms through which intratumoral microbiota influence tumor progression, a deeper understanding of their composition and functional roles in tumor dynamics is critical for the development of targeted therapies. In this review, we summarize current understanding and future perspectives of the bacterial lineages associated with different tumor types, discuss the mechanisms through which the intratumoral microbiome modulates tumor progression, and highlight emerging therapeutic strategies targeting intratumoral bacteria, including sonodynamic therapy (SDT), chemotherapy, immunotherapy, and oncolytic bacterial approaches.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105128"},"PeriodicalIF":5.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145992324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decoding the role of LRP1 in cancers: From molecular mechanisms to therapeutic opportunities 解读LRP1在癌症中的作用：从分子机制到治疗机会。

IF 5.6 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology

Pub Date : 2026-01-14 DOI: 10.1016/j.critrevonc.2026.105122

Dan Zou , Jike Hu , Yunpeng Wang , Puyi He , Lei Gao , Huanhuan Ma , Ying Yan , Yifan Li , Kai Wang , Weiyi Chen , Bofang Wang , Xiaotong Wang , Hao Chen

Low-density lipoprotein receptor-related protein 1 (LRP1), a key member of the Low-density lipoprotein receptor (LDLR) family, is a transmembrane receptor with a wide range of biological functions. It plays a crucial regulatory role in physiological processes such as lipid metabolism, extracellular matrix remodeling, and cell signal transduction. Recent studies have highlighted that LRP1 also plays a significant role in tumorigenesis by influencing tumor progression through its involvement in regulating tumor cell invasion and metastasis, angiogenesis, immune evasion, and metabolic reprogramming. However, the precise molecular mechanisms underlying these processes remain to be further elucidated. This review systematically summarizes the current understanding of LRP1's functional role across various tumor types, with particular emphasis on its regulatory mechanisms in tumor malignancy and the tumor microenvironment. Additionally, its involvement in treatment resistance and potential applications in drug delivery for brain tumors are discussed. This review aims to provide a theoretical basis for the development of LRP1 as a novel therapeutic target in cancer treatment and its potential translation into precision medicine.

低密度脂蛋白受体相关蛋白1 （Low-density lipoprotein receptor related protein 1, LRP1）是低密度脂蛋白受体（Low-density lipoprotein receptor， LDLR）家族的重要成员，是一种具有广泛生物学功能的跨膜受体。它在脂质代谢、细胞外基质重塑和细胞信号转导等生理过程中起着至关重要的调节作用。最近的研究表明，LRP1还通过参与调节肿瘤细胞的侵袭和转移、血管生成、免疫逃避和代谢重编程，影响肿瘤的进展，在肿瘤发生中发挥重要作用。然而，这些过程背后的精确分子机制仍有待进一步阐明。本文系统总结了目前对LRP1在不同肿瘤类型中的功能作用的认识，特别强调了其在肿瘤恶性和肿瘤微环境中的调节机制。此外，还讨论了其在脑肿瘤治疗耐药中的作用及其在药物输送中的潜在应用。本文综述旨在为LRP1作为一种新的肿瘤治疗靶点的开发及其在精准医学中的潜在转化提供理论依据。

{"title":"Decoding the role of LRP1 in cancers: From molecular mechanisms to therapeutic opportunities","authors":"Dan Zou , Jike Hu , Yunpeng Wang , Puyi He , Lei Gao , Huanhuan Ma , Ying Yan , Yifan Li , Kai Wang , Weiyi Chen , Bofang Wang , Xiaotong Wang , Hao Chen","doi":"10.1016/j.critrevonc.2026.105122","DOIUrl":"10.1016/j.critrevonc.2026.105122","url":null,"abstract":"<div><div>Low-density lipoprotein receptor-related protein 1 (LRP1), a key member of the Low-density lipoprotein receptor (LDLR) family, is a transmembrane receptor with a wide range of biological functions. It plays a crucial regulatory role in physiological processes such as lipid metabolism, extracellular matrix remodeling, and cell signal transduction. Recent studies have highlighted that LRP1 also plays a significant role in tumorigenesis by influencing tumor progression through its involvement in regulating tumor cell invasion and metastasis, angiogenesis, immune evasion, and metabolic reprogramming. However, the precise molecular mechanisms underlying these processes remain to be further elucidated. This review systematically summarizes the current understanding of LRP1's functional role across various tumor types, with particular emphasis on its regulatory mechanisms in tumor malignancy and the tumor microenvironment. Additionally, its involvement in treatment resistance and potential applications in drug delivery for brain tumors are discussed. This review aims to provide a theoretical basis for the development of LRP1 as a novel therapeutic target in cancer treatment and its potential translation into precision medicine.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"219 ","pages":"Article 105122"},"PeriodicalIF":5.6,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145992382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0